Future Science Group
TalkingTechniques with Mark Behlke: solving the off-target effects of CRISPR/Cas9
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:16:41
- Mas informaciones
Informações:
Sinopsis
We spoke to Mark Behlke, the chief scientific officer of Integrated DNA Technologies (IA, USA), about the current limitations of CRISPR/Cas9 techniques and the potential of the novel HiFI Cas9 enzyme to resolve these limitations, as shown in a sickle cell disease-causing mutation.
